Organon & Co. — Form 10-Q
Filed July 31, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
Organon & Co. signed three amendments (Nos. 8, 9, 10) with Samsung Bioepis between May 22 and June 1, 2026. Amendment 8 grants Organon exclusive rights to commercialize SB17 (ustekinumab/Stelara biosimilar) in Canada. Amendment 9 terminates Bevacizumab/Avastin (SB8) globally and narrows Trastuzumab/Herceptin (SB3) territory while extending SB2 and SB4 in select markets; Organon receives annual payments [REDACTED] through [REDACTED] and a transition/termination plan with compensation [REDACTED]. Amendment 10 further expands SB17 to Australia. Critical financial terms and product-specific pricing mechanisms redacted for competitive sensitivity.
Why this rating
Product portfolio adjustments—adding SB17 markets, exiting SB8 entirely, narrowing SB3 scope—constitute moderate restructuring. Relative to $2.5B market cap, the territorial shifts and extensions are material but not transformational. Redacted financial terms prevent full quantification. Neither positive nor negative dominates—reflects portfolio optimization, not growth or crisis.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.